---
title: 'Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse
  (&gt;24 months): the LATE-POD study'
date: '2024-05-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38754055/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240517181948&v=2.18.0.post9+e462414
source: Blood
description: Patients with mantle cell lymphoma (MCL) who experience first relapse/refractoriness
  can be categorized into early or late progression-of-disease (POD) groups, with
  a threshold of 24 months from the initial MCL diagnosis. Bruton tyrosine kinase
  inhibitors (BTKi) are established standard treatment at first relapse, but their
  effectiveness as compared to chemoimmunotherapy (CIT) in late-POD patients remains
  unknown. In this international, observational cohort study, we evaluated outcomes
  ...
disable_comments: true
---
Patients with mantle cell lymphoma (MCL) who experience first relapse/refractoriness can be categorized into early or late progression-of-disease (POD) groups, with a threshold of 24 months from the initial MCL diagnosis. Bruton tyrosine kinase inhibitors (BTKi) are established standard treatment at first relapse, but their effectiveness as compared to chemoimmunotherapy (CIT) in late-POD patients remains unknown. In this international, observational cohort study, we evaluated outcomes ...